Yuhan sealed a $80.9 million deal with California-based Gilead Sciences to supply pharmaceutical ingredients for the treatment of human immunodeficiency virus (HIV), the Korean drugmaker announced in an electronic disclosure on Friday.
Yuhan CEO Cho Wook-je speaks during a press conference held in western Seoul in August. [YONHAP]
Yuhan has secured an $80.9 million deal with California-based Gilead Sciences to supply pharmaceutical ingredients for the treatment of human immunodeficiency virus (HIV), the Korean drugmaker announced in an electronic disclosure on Friday.
The contract runs through Sept. 30, 2025, according to the regulatory filing.
The deal represents about 7.6 percent of Yuhan's annual sales from last year.
Following the announcement, Yuhan's shares surged 18.41 percent as of 10:12 a.m. on Friday.
![Yuhan CEO Cho Wook-je speaks during a press conference held in western Seoul in August. [YONHAP]](https://img1.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202409/20/koreajoongangdaily/20240920101330950kwtg.jpg)